MOUNTAIN VIEW, Calif., March 9 /PRNewswire/ -- MAP Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on developing novel treatments for respiratory and CNS diseases, today announced that it will present a company update at the Cowen & Company 27th Annual Health Care Conference in Boston, MA which is being held March 12 - 15, 2007 at the Boston Marriott Copley Place Hotel. Timothy S. Nelson, MAP Pharmaceuticals' President and CEO, will make the company's presentation on Monday, March 12, 2007, at 5:00 pm (ET).
About MAP Pharmaceuticals
Located in Mountain View, California, MAP Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on developing novel treatments for respiratory and CNS diseases. The Company has completed Phase 2 clinical trials in two development programs: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraines. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
MAP Pharmaceuticals, Inc.CONTACT: Lisa Johnson of MAP Pharmaceuticals, Inc., +1-650-386-3122,ljohnson@mappharma.com
Web site: http://www.mappharma.com/
